Therapy With an Oxytocin Adjunct for Major Depression

• Status: Completed
• Trial end date: 2016-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the addition of intranasal oxytocin to the treatment of Major Depression using interpersonal psychotherapy. Half of the participants will receive a placebo adjunct to interpersonal psychotherapy, and the other half will receive oxytocin.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Concordia University; Concordia University, Montreal
• Treatments: Oxytocin

Criteria

Inclusion Criteria

• Current Major Depressive Episode

Exclusion Criteria

• Visual impairment

• Major medical illness [A condition that is chronic and associated with impaired functioning, distress, or frequent medical intervention), in particular, subjects with evidence or history of malignancy or any significant hematological, endocrine, cardiovascular (including any rhythm disorder), respiratory, renal, hepatic, or gastrointestinal disease

• Acute or chronic nasal diseases or obstruction

• Current (in the last month) use of any endocrine-relevant or psychotropic medication other than prescription antidepressants

• Current substance dependence or abuse

• Use of illicit drugs (stimulants, narcotics, psychedelics/hallucinogens, non-prescription medication) in the past 8 weeks

• Lifetime history of a psychosis (except if part of MDD) or pervasive developmental disorder

• Past or current comorbid axis-1 disorder except Dysthymia, Adjustment Disorder, Generalized Anxiety Disorder, Social Phobia, and Specific Phobia.

• Female Only: Females of child bearing potential cannot be pregnant or breastfeeding in order to participate in this study. They must not be planning to become pregnant, and must be willing to use appropriate contraception throughout the study.

• Female Only: To control for hormonal changes related to pregnancy, females will also be excluded if they have previously given birth.